@Ville__7 Profile picture

Ville

@Ville__7

IT expert / biotech investor / father of 2

Similar User
German Biotech photo

@GermanBiotech

Epoch photo

@EpochSwing

tk photo

@degrader_junkie

The Pathfinder photo

@path1finder

Dr. Long photo

@LuciusJameson

Complexificator photo

@Complexificator

EC2 photo

@Ec250940387Ec2

Franca_ole photo

@Franca_ole

Bon Wood photo

@ny1972_47

Coyote photo

@coyotebioscav

Phil Kalt photo

@philkalt

gmt999 photo

@gmt9992

EM photo

@8thKingofRome

Eulers Analyst photo

@EulersAnalyst

msp12389 photo

@msp12389

Ville Reposted

"The U.S. Energy Department has concluded that the Covid pandemic most likely arose from a laboratory leak, according to a classified intelligence report recently provided to the White House and key members of Congress." wsj.com/articles/covid…


Ville Reposted

$ATNM Doubling of OS (6.4 mo vs 3.2 mo) with significantly better quality of life (fewer side effects), plus a double-digit percentage of long-term survivors ... at first glance, this looks very good. Crossover patients also benefit significantly from treatment with Iomab-B.


$ATNM ad-hoc DMC meeting happening before year end confirmed by todays PR. "With this in mind, we look forward to guidance on Iomab-B expected from the ad-hoc DMC meeting before year-end." Should finally bring movement into the stock price.

$ATNM Interim data (dCR at 180d) of SIERRA trial just around the corner. "...and now focus our complete attention on the ad hoc interim analysis that will be complete in the coming weeks" ir.actiniumpharma.com/press-releases…



$ATNM Interim data (dCR at 180d) of SIERRA trial just around the corner. "...and now focus our complete attention on the ad hoc interim analysis that will be complete in the coming weeks" ir.actiniumpharma.com/press-releases…


$XNCR - CD28 Bispecific collaboration with Janssen / $JNJ. $50 million upfront payment. Nice. investors.xencor.com/news-releases/…


Ville Reposted

$ATNM Lintuzumab Ac225 in relapsed/refractory AML. Excellent interim results! ashpublications.org/blood/article/…

Tweet Image 1

$XNCR Xtend™ XmAb® Antibody Technology👇 VIR-7831 for the treatment of COVID-19 in Phase 3 started investors.vir.bio/news-releases/…


Uptake of #Monjuvi #tafasitamab in US seems good (slide 59 of $MOR $INCY presentation) Already >100 patients within first 2 months get their treatment. Translates into one year run rate of 600 patients/y 500-750M $ as projected peak sales seems conservative to me (also $XNCR)


News rich period for $EXEL starting this weekend ....

Gut feeling $EXEL could outperform $XBI in the coming months Especially interesting(12/24 m): * detailed Checkmate-9R results (1st l. RCC) at @myESMO 2020 * further data of COSMIC-021 trial cohorts;pivotal starts * HCC 1st l. data COSMIC-312 * XL092 potential as a "better cabo"?

Tweet Image 1


You will get burned when you ignore pipeline, fundamentals, upcoming positive catalysts and revenue potential completely. Lesson to learn: Don't just look at TA whe in comes to #biotech. $EXEL

$EXEL phase 3 data out this month - remain overall bearish going forward this stock as long its below 30-35 and cant regain these levels. #Bearish take care

Tweet Image 1


Iconic Therapeutics and $EXEL|s ICON-2 program is an ADC with ZymeLink™ technology -> $ZYME.

Just announced: Promising preclinical data @World_ADC for Iconic Therapeutics’ TF-targeting #ADC, which is the subject of an exclusive option and license agreement with $EXEL. Details here: bit.ly/2RtHxNG

Tweet Image 1


Loading...

Something went wrong.


Something went wrong.